Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Shares Outstanding (Diluted Average) (2024 - 2026)

Contineum Therapeutics' Shares Outstanding (Diluted Average) history spans 3 years, with the latest figure at $37.3 million for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) rose 44.34% to $37.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $37.3 million through Mar 2026, up 44.34% year-over-year, with the annual reading at $27.7 million for FY2025, 43.14% up from the prior year.
  • Shares Outstanding (Diluted Average) came in at $37.3 million for Q1 2026, up from $27.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $37.3 million in Q1 2026 to a low of $19.4 million in Q4 2024.
  • The 3-year median for Shares Outstanding (Diluted Average) is $26.8 million (2025), against an average of $27.6 million.
  • Year-over-year, Shares Outstanding (Diluted Average) soared 43.14% in 2025 and then soared 44.34% in 2026.
  • Contineum Therapeutics' Shares Outstanding (Diluted Average) stood at $19.4 million in 2024, then skyrocketed by 43.14% to $27.7 million in 2025, then skyrocketed by 34.79% to $37.3 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Shares Outstanding (Diluted Average) are $37.3 million (Q1 2026), $27.7 million (Q4 2025), and $25.9 million (Q1 2025).